Given the expanding evidence for Nrf2 as a central regulator of oxidative stress, mitochondrial integrity, RNA metabolism, proteostasis, and neuroinflammation, pharmacological modulation of this pathway has emerged as a promising strategy in ALS. This evidence concerns the gene NFE2L2 and amyotrophic lateral sclerosis.